checkAd
    Startseite > Aktien > Quince Therapeutics > Nachrichten
    Quince Therapeutics Aktie
    0,9500
     
    USD
    +3,26 %
    +0,0300 USD
    Letzter Kurs 11.05.24 Nasdaq
    0,9100
     
    USD
    1.200 STK
    Geldkurs 10.05.24
    0,9500
     
    USD
    1.000 STK
    Briefkurs 10.05.24
    ISIN: US22053A1079 · WKN: A2PHHD · SYM: QNCX · USA

    Neueste Nachrichten

    Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
    06.05.24 · Business Wire (engl.) · Quince Therapeutics
    Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
    01.04.24 · Business Wire (engl.) · Quince Therapeutics
    Quince Therapeutics Launches Scientific Advisory Board
    22.02.24 · Business Wire (engl.) · Quince Therapeutics
    Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
    15.02.24 · Business Wire (engl.) · Quince Therapeutics
    Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
    07.02.24 · Business Wire (engl.) · Quince Therapeutics
    Quince Therapeutics to Participate at Investor Events in January 2024
    04.01.24 · Business Wire (engl.) · Quince Therapeutics
    Quince Therapeutics Completes Acquisition of EryDel S.p.A.
    23.10.23 · Business Wire (engl.) · Quince Therapeutics
    U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
    28.09.23 · Business Wire (engl.) · Quince Therapeutics
    Quince Therapeutics Appoints Dr. Charles S. Ryan as President
    06.09.23 · Business Wire (engl.) · Quince Therapeutics
    Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023
    10.08.23 · Business Wire (engl.) · Quince Therapeutics
    Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
    24.07.23 · Business Wire (engl.) · Quince Therapeutics